Cryptome lures expat home for advisory role
Friday, 14 May, 2004
Melbourne-based proteomics researcher Cryptome Pharmaceuticals has lured Dr Paul Cossum, an Australian who for the last 20 years has worked in American biopharmas, to join the company. As a scientific consultant, Cossum will provide advice on drug development and regulatory affairs.
Both Cossum and recently-appointed Cryptome CEO Dr Jeffrey Travis moved to Australia from positions at early-stage privately-held biopharma NewBiotics Pharmaceuticals in San Diego.
Cossum was executive vice-president of drug development at NewBiotics. He has also worked in pre-clinical development at Arnoex Pharmaceuticals and Isis Pharmaceuticals. He began his career at Genentech, conducting research on recombinant human proteins.
Cryptome's technology uses proteolytic enzymes to break proteins into protein fragments, which are assayed for activity. Its first candidate drug is CR001, is an anti-coagulant compound.
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
